Bio-Rad Laboratories, Inc. (BIO)
After hours:
| Previous close | 353.03 |
| Open | 351.61 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's range | 349.27 - 354.76 |
| 52-week range | 344.63 - 509.62 |
| Volume | |
| Avg. volume | 188,822 |
| Market cap | 10.352B |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 2023 Healthcare Conference
HERCULES, Calif., August 28, 2023--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during Wells Fargo’s 2023 Healthcare Conference on Thursday, September 7 at 11:00 AM Eastern Time (8:00 AM Pacific Time).
- Business Wire
Bio-Rad Reports Second-Quarter 2023 Financial Results
HERCULES, Calif., August 03, 2023--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2023.
- Business Wire
Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement
HERCULES, Calif., & VENLO, the Netherlands, July 26, 2023--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.
